Pentaerythritol tris(3-(1-aziridinyl)propionate)

Catalog No. :
ACFABX185
CAS No. :
57116-45-7
Molecular Formula :
C20H33N3O7
Molecular Weight :
427.50

IUPAC Name:2-(((3-(aziridin-1-yl)propanoyl)oxy)methyl)-2-(hydroxymethyl)propane-1,3-diyl bis(3-(aziridin-1-yl)propanoate)

Pentaerythritol tris(3-(1-aziridinyl)propionate) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
500g99%$138.00Login to see priceIn stockInquiry
1000g99%$230.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NamePentaerythritol tris(3-(1-aziridinyl)propionate)
IUPAC Name2-(((3-(aziridin-1-yl)propanoyl)oxy)methyl)-2-(hydroxymethyl)propane-1,3-diyl bis(3-(aziridin-1-yl)propanoate)
MDL No.MFCD01757346
Molecular FormulaC20H33N3O7
Molecular Weight427.50
SMILESOCC(COC(=O)CCN1CC1)(COC(=O)CCN1CC1)COC(=O)CCN1CC1
InChI KeyKAPCRJOPWXUMSQ-UHFFFAOYSA-N
SynonymPentaerythritoltris(3-(1-aziridinyl)propionate) | CS-0158335 | Tox21_302250 | Xama 7 | BCP18152 | EINECS 260-568-2 | 3-(aziridin-1-yl)propanoate; 2,2-bis(hydroxymethyl)propane-1,3-diol;Pentaerythritol tris(3-(1-aziridinyl)propionate) | CAS-57116-45-7 | SC
CAS No.57116-45-7
PubChem CID92667

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H317-H319
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACFABX185 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFABX185 route product structure diagram
    ACFABX18557116-45-7 In Stock
Inquiry

2. ACFABX185 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFABX185 route product structure diagram
    ACFABX18557116-45-7 In Stock
Inquiry

Comments (0)